Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial

Authors

Siobhan Sutcliffe, Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine in St. Louis
Raphael P. Viscidi, Johns Hopkins University
Cathee Till, Fred Hutchinson Cancer Research Center
Phyllis J. Goodman, Fred Hutchinson Cancer Research Center
Ashraful M. Hoque, University of Texas M.D. Anderson Cancer Center
Ann W. Hsing, National Institutes of Health
Ian M. Thompson, University of Texas Health Science - San Antonio
Johnathan M. Zenilman, Johns Hopkins University
Angelo M. De Marzo, Johns Hopkins University
Elizabeth A. Platz, Johns Hopkins University

Document Type

Article

Journal

Cancer Epidemiology, Biomarkers & Prevention

Volume

19

Issue

2

Inclusive Pages

614-8

Publication Date

2010

Recommended Citation

Sutcliffe, Siobhan; Viscidi, Raphael P.; Till, Cathee; Goodman, Phyllis J.; Hoque, Ashraful M.; Hsing, Ann W.; Thompson, Ian M.; Zenilman, Johnathan M.; De Marzo, Angelo M.; and Platz, Elizabeth A., "Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial" (2010). Cancer Prevention Faculty Publications. Paper 3.
Retrieved from https://digitalcommons.wustl.edu/canpre_pubs/3